In vitro antifungal activity of 2-(3,4-dimethyl-2,5-dihydro-1H-pyrrol-2-yl)-1-methylethyl pentanoate, a dihydropyrrole derivative

References

1. Bartizal K., Gill C. J., Abruzzo G. K. & 8 other authors; 1997; In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob Agents Chemother 41:2326–2332
   [Google Scholar]
2. Dabur R., Ali M., Singh H., Gupta J., Sharma G. L. 2004; A novel antifungal pyrrole derivative from Datura metel leaves. Die Pharmazie 59:568–570
   [Google Scholar]
3. Denning D. W., Stevens D. A. 1990; Antifungal and surgical treatment of invasive aspergillosis review of 2121 published cases. Rev Infect Dis 12:1147–1201 [CrossRef]
   [Google Scholar]
4. Kurtz M. B., Heath I. B., Marrinan J., Dreikorn S., Onishi J., Douglas C. 1994; Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-d-glucan synthase. Antimicrob Agents Chemother 38:1480–1489 [CrossRef]
   [Google Scholar]
5. Meyer J. D. 1990; Fungal infection in bone marrow transplants patients. Semin Oncol 17:10–13
   [Google Scholar]
6. NCCLS 1997 Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, document M27-A Wayne, PA: National Committee for Clinical Laboratory Standards;
   [Google Scholar]
7. Pfaller M. A. 1994; Epidemiology and control of fungal infections. Clin Infect Dis 19 Suppl 1:S8–S13
   [Google Scholar]
8. Pfaller M. A., Jones R. N., Messer S. A., Edmond M. B., Wenzel R. P. 1998a; National surveillance of nosocomial blood stream isolates due to Candida albicans : frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn Microbiol Infect Dis 31:327–332 [CrossRef]
   [Google Scholar]
9. Pfaller M. A., Marco F., Messer S. A., Jones R. N. 1998b; In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus , Fusarium , Rhizopus , and other filamentous fungi. Diagn Microbiol Infect Dis 30:251–255 [CrossRef]
   [Google Scholar]
10. Pfaller M. A., Messer S. A., Hollis R. J., Jones R. N., Doern G. V., Brandt M. E., Hajjeh R. A. 1999; Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn Microbiol Infect Dis 33:217–222 [CrossRef]
    [Google Scholar]
11. Powderly W. G. 1994; Resistant candidiasis. AIDS Res Hum Retrovir 10:925–929 [CrossRef]
    [Google Scholar]
12. Powderly W. G., Kobayashi G. S., Herzig G. P., Medoff G. 1988; Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med 84:826– 826 [CrossRef]
    [Google Scholar]
13. Randhawa H. S., Khan Z. U. 1987; Acute pulmonary mycoses in India: current status and laboratory diagnosis aspects. Indian J Tuberc 34:3–11
    [Google Scholar]
14. Rex J. H., Pfaller M. A., Rinaldi M. G., Polak A., Galgiani J. N. 1993; Antifungal susceptibility testing. Clin Microbiol Rev 6:367–381
    [Google Scholar]
15. Rex J. H., Cooper C. R., Merz W. G., Galgiani J. N., Anaissie E. J. 1995; Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother 39:906–909 [CrossRef]
    [Google Scholar]
16. Sharma G. L., Dabur R., Ali M. 2004; A novel antifungal molecule 2-(3,4-dimethyl-2,5-dihydro-1h-pyrrol-2-yl)-1-methylethyl pentanoate. US patent no:6713504
    [Google Scholar]
17. Zhanel G. G., Karlowsky J. A., Harding G. A. J., Balko T. V., Zelenitsky S. A., Friesen M., Kabani A., Turik M., Hoban D. J. 1997; In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans , Blastomyces dermatitidis , and Aspergillus species. Antimicrob Agents Chemother 41:863–865
    [Google Scholar]